- Clinical Trials
Our technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options.
We are developing gene therapies for patients with cancer and diabetes to bring new therapies to large patient populations. Our lead product candidate, REQORSA™ immunogene therapy, is designed to be administered in combination with other therapies, including targeted therapies and immunotherapies, for non-small cell lung cancer.
We have assembled a multidisciplinary team of executives and advisors with broad business experience in the biotech and pharmaceutical industries, and research and clinical experience at preeminent medical and academic institutions around the world. Our management team pairs an unmatched expertise with a knack for innovation in research.
At Genprex, we are committed to developing life-changing gene therapies for patients with cancer and diabetes through unique, innovative science. We are dedicated in our efforts to helping patients with limited or no treatment options to have access to new and advanced therapies to more effectively treat their disease.
Presentation to Highlight Company’s Recent Advancements on its Upcoming Clinical Trials for the Treatment of Non-Small Cell Lung Cancer
Presentation to Highlight the Company’s Recent Progress on its Upcoming Clinical Trials for the Treatment of Non-Small Cell Lung Cancer
Company passes final release tests of scaled-up clinical grade production to supply drug product for upcoming Acclaim-1 and Acclaim-2 clinical trials in lung cancer
What do small cap and micro cap investors look at? We thought you’d want to know what we discovered when we took a look back at Channelchek’s most popular content of 2020.
We’re passionate about the work we’re doing to revolutionize the fight against cancer and diabetes. Whether you or somebody you know is afflicted by one of these diseases, you are a medical practioner interested in our treatment options, or you are an investor that has supported our fight, we want to keep you informed of our advancements. For up-to-the-minute company news delivered straight to your inbox, sign up for our email newsletter.